Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casppian Study: FP-001 42 mg in Central Precocious Puberty
NCT05493709Phase 3Completed
- Sponsor
- Foresee Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in central precocious puberty (CPP), sponsored by Foresee Pharmaceuticals. Primary endpoint: Efficacy of Leuprolide Mesylate at 48 weeks. Started Jun 2023; status: completed.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT05493709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493709.